- 米国企業
- LIGAND PHARMACEUTICALS INC
LIGAND PHARMACEUTICALS INCLGND
| 2011年
12月31日 | 2012年
12月31日 | 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Net income (loss) | - | - | - | 11 | 255 | -2 | 13 | 143 | 629 | -3 | 57 | -33 | - |
|---|
| Net income (loss) | 10 | -1 | 11 | 12 | 257 | -2 | 13 | 143 | 629 | -3 | 57 | -33 | 52 |
|---|
| Gain on sale of Pelican | - | - | - | - | - | - | - | - | - | 17 | - | - | 2 |
|---|
| Change in estimated fair value of contingent liabilities | -1 | -2 | -4 | -5 | -5 | -3 | -3 | -3 | 0 | -1 | 37 | 1 | 0 |
|---|
| Depreciation, Depletion and Amortization | 3 | 3 | 3 | 3 | 3 | 11 | 12 | 15 | 18 | 26 | 51 | 52 | 37 |
|---|
| Loss (gain) short-term investments | - | - | - | - | - | - | - | - | - | -17 | -4 | 29 | 46 |
|---|
| Amortization/accretion of premium (discount) on investments, net | - | - | - | - | - | -0 | 0 | 5 | 10 | -1 | -0 | -0 | 1 |
|---|
| Amortization of debt discount and issuance fees | - | - | - | - | 10 | 11 | 12 | 44 | 30 | 23 | 17 | 1 | 0 |
|---|
| Loss (gain) on debt extinguishment | - | - | - | - | - | - | - | - | - | - | -7 | 4 | - |
|---|
| Gain on derivative instruments | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Amortization of commercial license and other economic rights | - | - | - | - | - | - | - | - | 25 | 2 | -0 | -0 | -1 |
|---|
| Loss (gain) on debt extinguishment | - | - | - | - | - | - | - | - | - | - | -7 | 4 | - |
|---|
| Lease amortization expense | - | - | - | - | - | - | - | - | - | - | - | 6 | 2 |
|---|
| Amortization of commercial license and other economic rights | - | - | - | - | - | - | - | - | 25 | 2 | -0 | -0 | -1 |
|---|
| Share-based compensation | 3 | 4 | 6 | 11 | 12 | 19 | 25 | 21 | 25 | 31 | 39 | 60 | 26 |
|---|
| Adjustment to credit loss reserves of commercial license rights | - | - | - | - | - | - | - | - | - | - | - | - | 4 |
|---|
| Deferred income taxes, net | 13 | 1 | -0 | -0 | 220 | -11 | -45 | -30 | -75 | 19 | 9 | -21 | -12 |
|---|
| Impairment loss of commercial license rights | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Other | - | - | - | - | 0 | - | - | - | -1 | 3 | 2 | 0 | 1 |
|---|
| Lease amortization expense | - | - | - | - | - | - | - | - | - | - | - | 6 | 2 |
|---|
| Accounts receivable, net | 4 | -2 | -2 | 10 | -6 | 9 | 8 | 30 | -25 | 26 | 29 | -55 | 3 |
|---|
| Inventory | -1 | -1 | -1 | -4 | 0 | 0 | 1 | 3 | 2 | 18 | 0 | -12 | 11 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Other economic rights | - | - | - | - | - | - | - | - | - | - | - | - | 5 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Share-based compensation | 3 | 4 | 6 | 11 | 12 | 19 | 25 | 21 | 25 | 31 | 39 | 60 | 26 |
|---|
| Losses from equity method investment in Primrose Bio | - | - | - | - | -5 | -23 | -2 | 42 | 3 | - | - | - | -2 |
|---|
| Deferred income taxes, net | 13 | 1 | -0 | -0 | 220 | -11 | -45 | -30 | -75 | 19 | 9 | -21 | -12 |
|---|
| Other | - | - | - | - | 0 | - | - | - | -1 | 3 | 2 | 0 | 1 |
|---|
| Accounts receivable, net | 4 | -2 | -2 | 10 | -6 | 9 | 8 | 30 | -25 | 26 | 29 | -55 | 3 |
|---|
| Inventory | -1 | -1 | -1 | -4 | 0 | 0 | 1 | 3 | 2 | 18 | 0 | -12 | 11 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Other economic rights | - | - | - | - | - | - | - | - | - | - | - | - | 5 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Net cash provided by operating activities | -1 | 0 | 21 | 21 | 42 | 63 | 94 | 194 | -29 | 55 | 79 | 138 | 50 |
|---|
| Net income (loss) | - | - | - | 11 | 255 | -2 | 13 | 143 | 629 | -3 | 57 | -33 | - |
|---|
| Net income (loss) | 10 | -1 | 11 | 12 | 257 | -2 | 13 | 143 | 629 | -3 | 57 | -33 | 52 |
|---|
| Gain on sale of Pelican | - | - | - | - | - | - | - | - | - | 17 | - | - | 2 |
|---|
| Change in estimated fair value of contingent liabilities | -1 | -2 | -4 | -5 | -5 | -3 | -3 | -3 | 0 | -1 | 37 | 1 | 0 |
|---|
| Depreciation, Depletion and Amortization | 3 | 3 | 3 | 3 | 3 | 11 | 12 | 15 | 18 | 26 | 51 | 52 | 37 |
|---|
| Loss (gain) short-term investments | - | - | - | - | - | - | - | - | - | -17 | -4 | 29 | 46 |
|---|
| Amortization/accretion of premium (discount) on investments, net | - | - | - | - | - | -0 | 0 | 5 | 10 | -1 | -0 | -0 | 1 |
|---|
| Amortization of debt discount and issuance fees | - | - | - | - | 10 | 11 | 12 | 44 | 30 | 23 | 17 | 1 | 0 |
|---|
| Loss (gain) on debt extinguishment | - | - | - | - | - | - | - | - | - | - | -7 | 4 | - |
|---|
| Gain on derivative instruments | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Amortization of commercial license and other economic rights | - | - | - | - | - | - | - | - | 25 | 2 | -0 | -0 | -1 |
|---|
| Loss (gain) on debt extinguishment | - | - | - | - | - | - | - | - | - | - | -7 | 4 | - |
|---|
| Lease amortization expense | - | - | - | - | - | - | - | - | - | - | - | 6 | 2 |
|---|
| Amortization of commercial license and other economic rights | - | - | - | - | - | - | - | - | 25 | 2 | -0 | -0 | -1 |
|---|
| Share-based compensation | 3 | 4 | 6 | 11 | 12 | 19 | 25 | 21 | 25 | 31 | 39 | 60 | 26 |
|---|
| Adjustment to credit loss reserves of commercial license rights | - | - | - | - | - | - | - | - | - | - | - | - | 4 |
|---|
| Deferred income taxes, net | 13 | 1 | -0 | -0 | 220 | -11 | -45 | -30 | -75 | 19 | 9 | -21 | -12 |
|---|
| Impairment loss of commercial license rights | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Other | - | - | - | - | 0 | - | - | - | -1 | 3 | 2 | 0 | 1 |
|---|
| Lease amortization expense | - | - | - | - | - | - | - | - | - | - | - | 6 | 2 |
|---|
| Accounts receivable, net | 4 | -2 | -2 | 10 | -6 | 9 | 8 | 30 | -25 | 26 | 29 | -55 | 3 |
|---|
| Inventory | -1 | -1 | -1 | -4 | 0 | 0 | 1 | 3 | 2 | 18 | 0 | -12 | 11 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Other economic rights | - | - | - | - | - | - | - | - | - | - | - | - | 5 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Share-based compensation | 3 | 4 | 6 | 11 | 12 | 19 | 25 | 21 | 25 | 31 | 39 | 60 | 26 |
|---|
| Losses from equity method investment in Primrose Bio | - | - | - | - | -5 | -23 | -2 | 42 | 3 | - | - | - | -2 |
|---|
| Deferred income taxes, net | 13 | 1 | -0 | -0 | 220 | -11 | -45 | -30 | -75 | 19 | 9 | -21 | -12 |
|---|
| Other | - | - | - | - | 0 | - | - | - | -1 | 3 | 2 | 0 | 1 |
|---|
| Accounts receivable, net | 4 | -2 | -2 | 10 | -6 | 9 | 8 | 30 | -25 | 26 | 29 | -55 | 3 |
|---|
| Inventory | -1 | -1 | -1 | -4 | 0 | 0 | 1 | 3 | 2 | 18 | 0 | -12 | 11 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Other economic rights | - | - | - | - | - | - | - | - | - | - | - | - | 5 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Accounts payable and accrued liabilities | -12 | -5 | -3 | -3 | -4 | -2 | -2 | -5 | -7 | -1 | 3 | -3 | -5 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Income taxes receivable and payable | - | - | - | - | - | - | - | - | 11 | -9 | 4 | -2 | 2 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -1 | - | 29 | -18 | -6 | 0 |
|---|
| Other assets and liabilities | - | - | - | - | - | - | - | - | - | - | - | -6 | 10 |
|---|
| Net cash provided by operating activities | -1 | 0 | 21 | 21 | 42 | 63 | 94 | 194 | -29 | 55 | 79 | 138 | 50 |
|---|
| Cash paid for acquisition, net of cash and restricted cash acquired | - | - | 4 | 1 | 4 | 93 | 27 | 6 | 12 | 405 | - | - | 10 |
|---|
| Purchase of commercial license rights | - | - | - | - | - | 18 | - | 10 | - | - | - | - | 50 |
|---|
| Purchases of property and equipment | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 3 | 4 | 9 | 18 | 4 |
|---|
| Purchases of short-term investments | 10 | - | - | - | 166 | 164 | 254 | 1,434 | 2,357 | 423 | 181 | 51 | 127 |
|---|
| Proceeds from commercial license rights | - | - | - | - | - | - | - | - | - | 1 | 0 | 0 | 0 |
|---|
| Proceeds from sale of short-term investments | 19 | 10 | - | 2 | 16 | 25 | 87 | 132 | 536 | 395 | 154 | 210 | 149 |
|---|
| Proceeds from maturity of short-term investments | - | - | - | - | 57 | 119 | 110 | 893 | 1,495 | 644 | 67 | 25 | 45 |
|---|
| Cash paid for equity method investment | - | - | - | - | - | - | - | - | - | - | - | - | 15 |
|---|
| Proceeds on sale of Vernalis R&D, net | - | - | - | - | - | - | - | - | - | 22 | - | - | - |
|---|
| Cash paid for Novan acquisition, net of restricted cash received | - | - | 4 | 1 | 4 | 93 | 27 | 6 | 12 | 405 | - | - | 10 |
|---|
| Other, net | 0 | 0 | 0 | -0 | - | - | - | - | 5 | -2 | 1 | 1 | - |
|---|
| Net cash (used) provided in investing activities | -25 | 1 | -5 | -2 | -113 | -143 | -84 | -423 | 467 | 232 | 31 | 164 | -12 |
|---|
| Net cash transferred to OmniAb at separation | - | - | - | - | - | - | - | - | - | - | - | 2 | - |
|---|
| Repayment at maturity/repurchase of 2023 Notes | - | 10 | 20 | 9 | - | - | - | 218 | 27 | 222 | 156 | 261 | 77 |
|---|
| Payments under finance lease obligations | - | - | - | - | - | - | - | - | - | 10 | 9 | 0 | 0 |
|---|
| Cash paid for OmniAb transaction costs | - | - | - | - | - | - | - | - | - | - | - | 7 | - |
|---|
| Proceeds from bond hedge settlement | - | - | - | - | - | - | - | 440 | 12 | - | 19 | 0 | - |
|---|
| Cash paid for debt issuance costs | - | - | - | 6 | - | - | - | 17 | - | - | - | - | 1 |
|---|
| Proceeds from Stock Options Exercised | - | 1 | 3 | 5 | 9 | 6 | 5 | 20 | 3 | 3 | 34 | 3 | 22 |
|---|
| Proceeds from bond hedge settlement | - | - | - | - | - | - | - | 440 | 12 | - | 19 | 0 | - |
|---|
| Taxes paid related to net share settlement of equity awards | - | - | - | - | - | 1 | 10 | 4 | 4 | 1 | 6 | 8 | 5 |
|---|
| Proceeds from Stock Options Exercised | - | 1 | 3 | 5 | 9 | 6 | 5 | 20 | 3 | 3 | 34 | 3 | 22 |
|---|
| Share repurchases | 0 | - | - | 68 | 0 | 4 | 2 | 123 | 453 | 78 | - | - | - |
|---|
| Taxes paid related to net share settlement of equity awards | - | - | - | - | - | 1 | 10 | 4 | 4 | 1 | 6 | 8 | 5 |
|---|
| Repurchase of warrants | - | - | - | - | - | - | - | 30 | 0 | - | 18 | - | - |
|---|
| Payments to CVR Holders | - | - | - | - | - | - | - | 0 | 3 | 2 | 1 | 2 | - |
|---|
| Net cash used in financing activities | 30 | 4 | -16 | 130 | 8 | 2 | -8 | 329 | -485 | -311 | -138 | -276 | -60 |
|---|
| Net increase (decrease) in cash, cash equivalents, and restricted cash | - | - | - | - | - | - | - | 99 | -48 | -24 | -28 | 25 | -22 |
|---|
| Interest paid | - | - | - | - | - | - | - | 2 | 6 | 4 | 3 | 1 | 0 |
|---|
| Taxes paid | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 104 | 2 | 4 | 12 | 9 |
|---|
| Net cash paid for Novan | - | - | 4 | 1 | 4 | 93 | 27 | 6 | 12 | 405 | - | - | 10 |
|---|
| Accrued inventory purchases | - | - | - | - | - | 1 | 1 | 2 | 0 | 2 | 2 | - | - |
|---|
| Accrued Primrose transaction costs | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Unrealized Gain (Loss) on Investments | - | - | 3 | 4 | 3 | -1 | 0 | 0 | 0 | -0 | -0 | -0 | 0 |
|---|
| Accrued royalty from commercial license rights | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Accrued fixed asset purchases | - | - | - | - | - | - | - | - | 0 | 0 | 2 | 2 | - |
|---|
| Accrued commercial license rights purchases | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Accrued debt issuance costs | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Accrued fixed asset purchases | - | - | - | - | - | - | - | - | 0 | 0 | 2 | 2 | - |
|---|
| Accrued inventory purchases | - | - | - | - | - | 1 | 1 | 2 | 0 | 2 | 2 | - | - |
|---|
| Unrealized Gain (Loss) on Investments | - | - | 3 | 4 | 3 | -1 | 0 | 0 | 0 | -0 | -0 | -0 | 0 |
|---|
| Cash paid for acquisition, net of cash and restricted cash acquired | - | - | 4 | 1 | 4 | 93 | 27 | 6 | 12 | 405 | - | - | 10 |
|---|
| Purchase of commercial license rights | - | - | - | - | - | 18 | - | 10 | - | - | - | - | 50 |
|---|
| Purchases of property and equipment | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 3 | 4 | 9 | 18 | 4 |
|---|
| Purchases of short-term investments | 10 | - | - | - | 166 | 164 | 254 | 1,434 | 2,357 | 423 | 181 | 51 | 127 |
|---|
| Proceeds from commercial license rights | - | - | - | - | - | - | - | - | - | 1 | 0 | 0 | 0 |
|---|
| Proceeds from sale of short-term investments | 19 | 10 | - | 2 | 16 | 25 | 87 | 132 | 536 | 395 | 154 | 210 | 149 |
|---|
| Proceeds from maturity of short-term investments | - | - | - | - | 57 | 119 | 110 | 893 | 1,495 | 644 | 67 | 25 | 45 |
|---|
| Cash paid for equity method investment | - | - | - | - | - | - | - | - | - | - | - | - | 15 |
|---|
| Proceeds on sale of Vernalis R&D, net | - | - | - | - | - | - | - | - | - | 22 | - | - | - |
|---|
| Cash paid for Novan acquisition, net of restricted cash received | - | - | 4 | 1 | 4 | 93 | 27 | 6 | 12 | 405 | - | - | 10 |
|---|
| Other, net | 0 | 0 | 0 | -0 | - | - | - | - | 5 | -2 | 1 | 1 | - |
|---|
| Net cash (used) provided in investing activities | -25 | 1 | -5 | -2 | -113 | -143 | -84 | -423 | 467 | 232 | 31 | 164 | -12 |
|---|
| Net cash transferred to OmniAb at separation | - | - | - | - | - | - | - | - | - | - | - | 2 | - |
|---|
| Repayment at maturity/repurchase of 2023 Notes | - | 10 | 20 | 9 | - | - | - | 218 | 27 | 222 | 156 | 261 | 77 |
|---|
| Payments under finance lease obligations | - | - | - | - | - | - | - | - | - | 10 | 9 | 0 | 0 |
|---|
| Cash paid for OmniAb transaction costs | - | - | - | - | - | - | - | - | - | - | - | 7 | - |
|---|
| Proceeds from bond hedge settlement | - | - | - | - | - | - | - | 440 | 12 | - | 19 | 0 | - |
|---|
| Cash paid for debt issuance costs | - | - | - | 6 | - | - | - | 17 | - | - | - | - | 1 |
|---|
| Proceeds from Stock Options Exercised | - | 1 | 3 | 5 | 9 | 6 | 5 | 20 | 3 | 3 | 34 | 3 | 22 |
|---|
| Proceeds from bond hedge settlement | - | - | - | - | - | - | - | 440 | 12 | - | 19 | 0 | - |
|---|
| Taxes paid related to net share settlement of equity awards | - | - | - | - | - | 1 | 10 | 4 | 4 | 1 | 6 | 8 | 5 |
|---|
| Proceeds from Stock Options Exercised | - | 1 | 3 | 5 | 9 | 6 | 5 | 20 | 3 | 3 | 34 | 3 | 22 |
|---|
| Share repurchases | 0 | - | - | 68 | 0 | 4 | 2 | 123 | 453 | 78 | - | - | - |
|---|
| Taxes paid related to net share settlement of equity awards | - | - | - | - | - | 1 | 10 | 4 | 4 | 1 | 6 | 8 | 5 |
|---|
| Repurchase of warrants | - | - | - | - | - | - | - | 30 | 0 | - | 18 | - | - |
|---|
| Payments to CVR Holders | - | - | - | - | - | - | - | 0 | 3 | 2 | 1 | 2 | - |
|---|
| Net cash used in financing activities | 30 | 4 | -16 | 130 | 8 | 2 | -8 | 329 | -485 | -311 | -138 | -276 | -60 |
|---|
| Net increase (decrease) in cash, cash equivalents, and restricted cash | - | - | - | - | - | - | - | 99 | -48 | -24 | -28 | 25 | -22 |
|---|
| Interest paid | - | - | - | - | - | - | - | 2 | 6 | 4 | 3 | 1 | 0 |
|---|
| Taxes paid | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 104 | 2 | 4 | 12 | 9 |
|---|
| Net cash paid for Novan | - | - | 4 | 1 | 4 | 93 | 27 | 6 | 12 | 405 | - | - | 10 |
|---|
| Accrued inventory purchases | - | - | - | - | - | 1 | 1 | 2 | 0 | 2 | 2 | - | - |
|---|
| Accrued Primrose transaction costs | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Unrealized Gain (Loss) on Investments | - | - | 3 | 4 | 3 | -1 | 0 | 0 | 0 | -0 | -0 | -0 | 0 |
|---|
| Accrued royalty from commercial license rights | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Accrued fixed asset purchases | - | - | - | - | - | - | - | - | 0 | 0 | 2 | 2 | - |
|---|
| Accrued commercial license rights purchases | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Accrued debt issuance costs | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Accrued fixed asset purchases | - | - | - | - | - | - | - | - | 0 | 0 | 2 | 2 | - |
|---|
| Accrued inventory purchases | - | - | - | - | - | 1 | 1 | 2 | 0 | 2 | 2 | - | - |
|---|
| Unrealized Gain (Loss) on Investments | - | - | 3 | 4 | 3 | -1 | 0 | 0 | 0 | -0 | -0 | -0 | 0 |
|---|